ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

lurbinectedin

Also written as “Lurbinectedin”, “lurbinectedin (PM01183)” and “Lurbinectedin (PM01183)”.

Its studies are mostly in Small Cell Lung Carcinoma · Breast Neoplasms · Neoplasms · Sarcoma, Ewing · Leiomyosarcoma, led by 5 companies.

Drug pagePM 01183: every studyMany companies study it; this page follows only the 27 they lead. All 53 studies, academic ones too, with its approvals and label.
Furthest: phase 3, since Apr 10, 201527 company-led studies, 7 open or runningNext primary completion: Dec 31, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
PharmaMarits history only202 open or runningphase 3since Apr 10, 2015Apr 6, 2009Aug 30, 2029phase 3 · NCT06088290
Jazz Pharmaceuticalsits history only32 open or runningphase 2since Nov 8, 2021Nov 8, 2021Jan 28, 2028phase 2 · NCT05734066
Luye Pharma Group21 open or runningphase 3since Jul 3, 2024Nov 5, 2020Dec 31, 2027phase 3 · NCT06496048
Gilead Sciencesits history only11 open or runningphase 3since Jan 24, 2025Jan 24, 2025Oct 2029phase 3 · NCT06801834
Hoffmann-La Rocheits history only11 open or runningphase 3since Oct 12, 2021Oct 12, 2021none ahead

Also a collaborator on its studies: Jazz Pharmaceuticals Ireland.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Luye Pharma Group only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 5, 2020First study: phase 1 study in Advanced Solid TumorFirst studyNCT04638491 · 32 enrolled · China
  2. Jul 3, 2024Phase 3 study in Small Cell Lung CarcinomaNCT06496048 · 180 planned · China

Ahead

  1. Dec 31, 2027Primary completion: phase 3 study in Small Cell Lung CarcinomaNCT06496048

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 Luye Pharma Group leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06496048Small Cell Lung Carcinoma · China3RecruitingDec 31, 2027180
NCT04638491Advanced Solid Tumor · China1CompletedNov 4, 202332

How it is read

Names in the registry

  • “Lurbinectedin”, 13 entries
  • “lurbinectedin (PM01183)”, 6 entries
  • “Lurbinectedin (PM01183)”, 3 entries
  • “PM01183”, 3 entries
  • “Lurbinectedin (regions/countries where approved and available)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.